Response to hepatitis B vaccine in family members of HBsAg carriers
β Scribed by Anna Suk-Fong Lok; Matthew Mai-Tai Ng; Ching-Lung Lal; Pul-Chee Wu
- Publisher
- John Wiley and Sons
- Year
- 1986
- Tongue
- English
- Weight
- 410 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
β¦ Synopsis
The family members of HBsAg camers have an increased risk of hepatitis B virus (HBV) infection. 214 subjects from 98 families with no HBV markers were randomized to receive hepatitis B vaccine: HEVAC B (Institute Pasteur) or GCC VAC (Green Cross Corporation) at 0, 1, and 5 months. Of those who completed the course, 87.8% had an anti-HBs response of > 10 mIU/ml at 6 months. The response rate was similar for both sexes. There was a decrease in response rate and anti-HBs titre with age. The response rate for HEVAC B was 92.5% and GCC VAC 84.3%. The offspring had comparable response to the spouses who were not blood relatives of the index carriers, but this could be related to their younger age. Discriminant analysis showed that a higher anti-HBs titre was associated with HEVAC B, younger age, and less direct relationship with the index carrier.
π SIMILAR VOLUMES
Abbreviations: HBsAg, hepatitis B surface antigen; anti-HBs, hepatitis B surface antimonths. 2 From the 415 children, we recruited 16 chronically infected gen antibody; HBV, hepatitis B virus; PCR, polymerase chain reaction; PBMC, peripheral children who had cleared serum HBsAg for more than 2 years
The presence of hepatitis B virus DNA and anti-b was examined in a longitudinal study of 24 patients known to be &infected during the course from acute to chronic hepatitis B virus infection. Fifteen patients (63%) were hepatitis B virus DNA positive in the first serum sample. Eleven of 14 patients,
Screening for HBeAg and anti-HBe WM performed on 133 carriers of HBsAg in an institution for the mentally retarded. By radioimmunoassay, the prevalences of HBeAg and anti-me were determined to be 16 and 78%, respectively. J3BeAg prevalence WM significantly different in the following pairs of carrier
Nineteen healthy young adults were vaccinated with plasma-derived hepatitis B vaccine at months 0, 1, and 12, and their immune responses were compared to those of a similar group of 20 vaccinees immunized at months 0, 1, and 6. Late booster injections at 12 months produced nearly fivefold higher geo